[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522449":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":37,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":7,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":7,"studyType":84,"phases":7,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Zhongnan Hospital","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Zheng Hu, doctor","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Chen Cao, doctor","CONTACT","+8613986276703","caochen@zxhospital.com",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Department of Gynecologic Oncology","RECRUITING","Wuhan","Hubei","430062","China","CN",{"type":28,"coordinates":29},"Point",[30,31],114.26667,30.58333,{"lat":31,"lon":30},[34],{"name":10,"role":15,"phone":7,"phoneExt":7,"email":7},{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[38,40,43,45,47,49,51,53,55,57,59,61,63,65,67,69],{"name":39,"class":6},"Wuhan Central Hospital",{"name":41,"class":42},"Huanggang Maternal and Child Health Hospital","UNKNOWN",{"name":44,"class":42},"Guilin People's Hospital",{"name":46,"class":42},"Zaoyang Maternal and Child Health Hospital",{"name":48,"class":42},"Jingshan People's Hospital",{"name":50,"class":6},"Yichang Second People's Hospital",{"name":52,"class":42},"Wuhan Third People's Hospital",{"name":54,"class":42},"Dawu County People's Hospital",{"name":56,"class":42},"Yingshan County People's Hospital",{"name":58,"class":42},"Zhongxiang People's Hospital",{"name":60,"class":42},"Zhongxiang Maternal and Child Health Hospital",{"name":62,"class":42},"Wuxue First People's Hospital",{"name":64,"class":42},"The First People's Hospital of Tianmen",{"name":66,"class":42},"Huangmei County People's Hospital",{"name":68,"class":42},"Huangmei Maternal and Child Health Care Hospital",{"name":70,"class":42},"Gucheng County People's Hospital","100522449","cervical-cancer-screening-with-ngs-hpv-technology-based-on-menstrual-blood-100522449",false,"NCT06082765","Cervical Cancer Screening with NGS-HPV Technology Based on Menstrual Blood","Inclusion Criteria:\n\n1. plan to undergo cervical screening\n2. with regular menstruation (21-35 days)\n3. agree to participate in this study and have signed an informed consent form\n\nExclusion Criteria:\n\n1. with amenorrhea or menopause\n2. suffering from genital tract infection\n3. refuse to participate in this study",true,"FEMALE","20 Years","60 Years",{"count":82,"type":83},10000,"ESTIMATED","OBSERVATIONAL","Our study is a population-based, cross-sectional study. This study is conducted to recruit cervical cancer screening participants to evaluate the application value of using high-throughput sequencing technology to detect HPV in menstrual blood for cervical cancer screening. Our study is designed as a two-phase study :\n\nPhase I : This phase, which will be preparing to recruit 5,000 participants, evaluates the accuracy of menstrual blood (MB) self-sampling for detecting cervical intraepithelial neoplasia grade two or worse (CIN2+) in the general population, with a secondary objective to evaluate the Minipad as a special device to collect MB.\n\nPhase II : This phase, which will continue to recruit toward the 10,000-participant target, will evaluate additional molecular markers (specifically DNA methylation) to optimize alternative triage methods for HPV-positive women in menstrual blood (MB) self-sampling. This phase aims to further reduce unnecessary colposcopies while maintaining high sensitivity for CIN2+ detection.",[87],"Cervical Cancer",[89,90,91,92],"HPV","menstrual blood","cervical cancer","screening,","2025-02-17",{"date":95,"type":96},"2025-02-18","ACTUAL",{"date":98,"type":96},"2021-09-01",{"date":100,"type":83},"2028-03-31",{"name":5,"class":6},1]